252 related articles for article (PubMed ID: 17084174)
21. Clinical endpoints for drug development in prostate cancer.
Ramiah V; George DJ; Armstrong AJ
Curr Opin Urol; 2008 May; 18(3):303-8. PubMed ID: 18382240
[TBL] [Abstract][Full Text] [Related]
22. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
Carducci MA; Carroll PR
Urology; 2005 May; 65(5 Suppl):18-22; discussion 22. PubMed ID: 15885275
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell vaccines for the treatment of prostate cancer.
Lehrfeld TJ; Lee DI
Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
[TBL] [Abstract][Full Text] [Related]
24. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
Armstrong AJ; Febbo PG
Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: genes, environment, immunity and the use of immunotherapy.
Karan D; Thrasher JB; Lubaroff D
Prostate Cancer Prostatic Dis; 2008; 11(3):230-6. PubMed ID: 18283297
[TBL] [Abstract][Full Text] [Related]
26. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
[TBL] [Abstract][Full Text] [Related]
28. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.
Hege KM; Jooss K; Pardoll D
Int Rev Immunol; 2006; 25(5-6):321-52. PubMed ID: 17169779
[TBL] [Abstract][Full Text] [Related]
29. New developments in castrate-resistant prostate cancer.
Shore N; Mason M; de Reijke TM
BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
[TBL] [Abstract][Full Text] [Related]
30. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapies in castrate-resistant prostate cancer.
Lassi K; Dawson NA
Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
[TBL] [Abstract][Full Text] [Related]
32. Atrasentan for metastatic hormone refractory prostate cancer.
Murphy G
Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
[TBL] [Abstract][Full Text] [Related]
33. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
34. GVAX (Cell Genesys).
Dummer R
Curr Opin Investig Drugs; 2001 Jun; 2(6):844-8. PubMed ID: 11572668
[TBL] [Abstract][Full Text] [Related]
35. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant therapy and prostate cancer: what a urologist should know.
Namiki K; Rosser CJ
Curr Opin Urol; 2007 May; 17(3):188-93. PubMed ID: 17414517
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy and immunotherapy combination in advanced prostate cancer.
Slovin S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):90-100. PubMed ID: 22402350
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapies for non-metastatic prostate cancer: review of the literature.
Jereczek-Fossa BA; Curigliano G; Orecchia R
Onkologie; 2009 Jun; 32(6):359-63. PubMed ID: 19521126
[TBL] [Abstract][Full Text] [Related]
40. Immunologic approaches to the treatment of prostate cancer.
Harris DT; Matyas GR; Gomella LG; Talor E; Winship MD; Spitler LE; Mastrangelo MJ
Semin Oncol; 1999 Aug; 26(4):439-47. PubMed ID: 10482186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
